Tillkännagivande • Mar 13
KBG Corp., Annual General Meeting, Mar 30, 2026 KBG Corp., Annual General Meeting, Mar 30, 2026, at 10:00 Tokyo Standard Time. Location: auditorium, 44-86, sari-ro bangchukgol-gil, goesan-gun, chungcheongbuk-do, South Korea Upcoming Dividend • Dec 22
Upcoming dividend of ₩75.00 per share Eligible shareholders must have bought the stock before 29 December 2025. Payment date: 10 April 2026. Trailing yield: 1.7%. Lower than top quartile of South Korean dividend payers (3.6%). Higher than average of industry peers (1.3%). Reported Earnings • Nov 16
Third quarter 2025 earnings released: EPS: ₩45.00 (vs ₩60.00 in 3Q 2024) Third quarter 2025 results: EPS: ₩45.00 (down from ₩60.00 in 3Q 2024). Revenue: ₩4.71b (down 24% from 3Q 2024). Net income: ₩391.8m (down 25% from 3Q 2024). Profit margin: 8.3% (down from 8.4% in 3Q 2024). The decrease in margin was driven by lower revenue. Tillkännagivande • Nov 07
KBG Corp. announces Annual dividend, payable on April 10, 2026 KBG Corp. announced Annual dividend of KRW 75.0000 per share payable on April 10, 2026, ex-date on December 29, 2025 and record date on December 31, 2025. Reported Earnings • May 18
First quarter 2025 earnings released: EPS: ₩57.00 (vs ₩95.49 in 1Q 2024) First quarter 2025 results: EPS: ₩57.00 (down from ₩95.49 in 1Q 2024). Revenue: ₩6.09b (up 27% from 1Q 2024). Net income: ₩493.4m (down 41% from 1Q 2024). Profit margin: 8.1% (down from 17% in 1Q 2024). The decrease in margin was driven by higher expenses. Tillkännagivande • Feb 22
KBG Corp., Annual General Meeting, Mar 24, 2025 KBG Corp., Annual General Meeting, Mar 24, 2025, at 10:00 Tokyo Standard Time. Location: auditorium, 44-86, sari-ro bangchukgol-gil, sari-myeon, goesan-gun, chungcheongbuk-do, South Korea New Risk • Feb 15
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Market cap is less than US$100m (₩42.0b market cap, or US$29.2m). Buy Or Sell Opportunity • Jan 06
Now 20% overvalued Over the last 90 days, the stock has fallen 23% to ₩4,835. The fair value is estimated to be ₩4,029, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 5.5% over the last 3 years, while earnings per share has been flat. Upcoming Dividend • Dec 20
Upcoming dividend of ₩100.00 per share Eligible shareholders must have bought the stock before 27 December 2024. Payment date: 14 April 2025. Trailing yield: 2.2%. Lower than top quartile of South Korean dividend payers (3.9%). In line with average of industry peers (2.2%). New Risk • Dec 16
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (₩41.5b market cap, or US$28.9m). Valuation Update With 7 Day Price Move • Dec 09
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ₩3,890, the stock trades at a trailing P/E ratio of 7.2x. Average trailing P/E is 9x in the Chemicals industry in South Korea. Total loss to shareholders of 52% over the past three years. Buy Or Sell Opportunity • Nov 18
Now 23% overvalued Over the last 90 days, the stock has fallen 25% to ₩4,930. The fair value is estimated to be ₩4,000, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 5.5% over the last 3 years, while earnings per share has been flat. Valuation Update With 7 Day Price Move • Sep 08
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to ₩6,040, the stock trades at a trailing P/E ratio of 11.1x. Average trailing P/E is 10x in the Chemicals industry in South Korea. Total loss to shareholders of 30% over the past three years. New Risk • Aug 23
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩67.7b market cap, or US$50.7m). Valuation Update With 7 Day Price Move • Aug 23
Investor sentiment improves as stock rises 32% After last week's 32% share price gain to ₩7,750, the stock trades at a trailing P/E ratio of 14.3x. Average trailing P/E is 12x in the Chemicals industry in South Korea. Total loss to shareholders of 4.7% over the past three years. Valuation Update With 7 Day Price Move • Aug 05
Investor sentiment deteriorates as stock falls 19% After last week's 19% share price decline to ₩4,900, the stock trades at a trailing P/E ratio of 8.6x. Average trailing P/E is 13x in the Chemicals industry in South Korea. Total loss to shareholders of 44% over the past three years. Upcoming Dividend • Dec 20
Inaugural dividend of ₩99.50 per share Eligible shareholders must have bought the stock before 27 December 2023. Payment date: 08 April 2024. This is the first dividend for KBG since going public. The average dividend yield among industry peers is 1.8%. New Risk • Oct 23
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (14% average weekly change). Minor Risks Shareholders have been diluted in the past year (5.7% increase in shares outstanding). Market cap is less than US$100m (₩83.9b market cap, or US$62.0m). Valuation Update With 7 Day Price Move • Oct 23
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to ₩9,600, the stock trades at a trailing P/E ratio of 21.8x. Average trailing P/E is 13x in the Chemicals industry in South Korea. Total returns to shareholders of 46% over the past three years. Valuation Update With 7 Day Price Move • Aug 17
Investor sentiment improves as stock rises 28% After last week's 28% share price gain to ₩11,370, the stock trades at a trailing P/E ratio of 33.4x. Average trailing P/E is 14x in the Chemicals industry in South Korea. Total returns to shareholders of 38% over the past three years. Valuation Update With 7 Day Price Move • Jul 27
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to ₩8,900, the stock trades at a trailing P/E ratio of 26.1x. Average trailing P/E is 14x in the Chemicals industry in South Korea. Total returns to shareholders of 31% over the past three years. New Risk • Jun 09
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 5.7% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (20% average weekly change). Minor Risks Shareholders have been diluted in the past year (5.7% increase in shares outstanding). Market cap is less than US$100m (₩115.7b market cap, or US$89.6m). Valuation Update With 7 Day Price Move • May 23
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to ₩14,340, the stock trades at a trailing P/E ratio of 39.9x. Average trailing P/E is 16x in the Chemicals industry in South Korea. Total returns to shareholders of 117% over the past three years. Valuation Update With 7 Day Price Move • May 03
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₩16,260, the stock trades at a trailing P/E ratio of 41.3x. Average trailing P/E is 14x in the Chemicals industry in South Korea. Total returns to shareholders of 213% over the past three years. Valuation Update With 7 Day Price Move • Apr 19
Investor sentiment improves as stock rises 57% After last week's 57% share price gain to ₩16,830, the stock trades at a trailing P/E ratio of 42.8x. Average trailing P/E is 15x in the Chemicals industry in South Korea. Total returns to shareholders of 220% over the past three years. Valuation Update With 7 Day Price Move • Apr 04
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to ₩11,700, the stock trades at a trailing P/E ratio of 29.8x. Average trailing P/E is 14x in the Chemicals industry in South Korea. Total returns to shareholders of 137% over the past three years. Valuation Update With 7 Day Price Move • Mar 07
Investor sentiment improves as stock rises 42% After last week's 42% share price gain to ₩9,650, the stock trades at a trailing P/E ratio of 17.8x. Average trailing P/E is 13x in the Chemicals industry in South Korea. Total returns to shareholders of 76% over the past three years. Upcoming Dividend • Dec 21
Inaugural dividend of ₩100.00 per share Eligible shareholders must have bought the stock before 28 December 2022. Payment date: 10 April 2023. This is the first dividend for KBG since going public. The average dividend yield among industry peers is 2.4%. Reported Earnings • Nov 17
Third quarter 2022 earnings released: EPS: ₩169 (vs ₩117 in 3Q 2021) Third quarter 2022 results: EPS: ₩169 (up from ₩117 in 3Q 2021). Revenue: ₩6.29b (down 9.1% from 3Q 2021). Net income: ₩1.39b (up 45% from 3Q 2021). Profit margin: 22% (up from 14% in 3Q 2021). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 79% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Nov 03
Investor sentiment improved over the past week After last week's 15% share price gain to ₩6,130, the stock trades at a trailing P/E ratio of 12.4x. Average trailing P/E is 12x in the Chemicals industry in South Korea. Total loss to shareholders of 23% over the past three years. Valuation Update With 7 Day Price Move • Sep 27
Investor sentiment deteriorated over the past week After last week's 15% share price decline to ₩4,855, the stock trades at a trailing P/E ratio of 9.9x. Average trailing P/E is 12x in the Chemicals industry in South Korea. Total loss to shareholders of 36% over the past three years. Valuation Update With 7 Day Price Move • Jun 15
Investor sentiment deteriorated over the past week After last week's 16% share price decline to ₩6,280, the stock trades at a trailing P/E ratio of 12.2x. Average trailing P/E is 15x in the Chemicals industry in South Korea. Total loss to shareholders of 27% over the past year. Upcoming Dividend • Dec 22
Inaugural dividend of ₩75.00 per share Eligible shareholders must have bought the stock before 29 December 2021. Payment date: 11 April 2022. The company is not currently making a profit but it is cash flow positive. This is the first dividend for Korea Bio-GenLtd since going public. The average dividend yield among industry peers is 1.4%. Reported Earnings • Nov 16
Third quarter 2021 earnings released: EPS ₩117 (vs ₩121 in 3Q 2020) The company reported a soft third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: ₩6.91b (up 25% from 3Q 2020). Net income: ₩954.3m (down 2.2% from 3Q 2020). Profit margin: 14% (down from 18% in 3Q 2020). The decrease in margin was driven by higher expenses. Valuation Update With 7 Day Price Move • Sep 30
Investor sentiment improved over the past week After last week's 16% share price gain to ₩10,600, the stock trades at a trailing P/E ratio of 21.4x. Average trailing P/E is 19x in the Chemicals industry in South Korea. Total returns to shareholders of 34% over the past year. Tillkännagivande • May 13
Korea Bio-Gen Co.,Ltd announced that it has received KRW 5 billion in funding from Daegyeong Investment Co., Ltd. and another investor On May 12, 2021, Korea Bio-Gen Co.,Ltd (KOSDAQ:A318000) closed the transaction. Tillkännagivande • May 11
Korea Bio-Gen Co.,Ltd announced that it expects to receive KRW 5 billion in funding from Daegyeong Investment Co., Ltd. and another investor Korea Bio-Gen Co., Ltd. (KOSDAQ:A318000) announced that it will issue series 3 unregistered coupon nonguaranteed private convertible bond for gross proceeds of KRW 5,000,000,000 on May 10, 2021. The transaction will include participation from Core Mezzanine PJT Hedge Fund 2 for KRW 3,000,000,000 and existing investor Daegyeong Investment Co., Ltd. for KRW 2,000,000,000. The bonds does not bear any interest and matures on May 12, 2026. The bonds are convertible into 542,299 shares at a fixed conversion price of KRW 9,220 per share from May 12, 2022 to April 12, 2026. The expected subscription and payment date is May 12, 2021. The transaction is approved by the board of directors of the company. Tillkännagivande • Feb 25
Korea Bio-Gen Co.,Ltd, Annual General Meeting, Mar 26, 2021 Korea Bio-Gen Co.,Ltd, Annual General Meeting, Mar 26, 2021, at 10:00 Korea Standard Time. Valuation Update With 7 Day Price Move • Jan 21
Investor sentiment improved over the past week After last week's 29% share price gain to ₩10,950, the stock is trading at a trailing P/E ratio of 30.4x, up from the previous P/E ratio of 23.6x. This compares to an average P/E of 18x in the Chemicals industry in South Korea. Total returns to shareholders over the past year are 63%. Is New 90 Day High Low • Jan 21
New 90-day high: ₩10,950 The company is up 48% from its price of ₩7,390 on 23 October 2020. The South Korean market is up 31% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 39% over the same period. Is New 90 Day High Low • Jan 04
New 90-day high: ₩8,390 The company is up 2.0% from its price of ₩8,260 on 06 October 2020. The South Korean market is up 21% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 22% over the same period. Upcoming Dividend • Dec 22
First Dividend Is ₩50.00 Per Share Will be paid on the 10th of April to those who are registered shareholders by the 29th of December. This is the first dividend for Korea Bio-GenLtd since going public. The average dividend yield among industry peers is 0.9%. Is New 90 Day High Low • Oct 26
New 90-day low: ₩6,880 The company is down 4.0% from its price of ₩7,160 on 28 July 2020. The South Korean market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 22% over the same period.